A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
about
Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applicationsDendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issuesLigand-based targeted therapy: a novel strategy for hepatocellular carcinomaEngineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic DeliveryColocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy.Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release.A light-controlled switch after dual targeting of proliferating tumor cells via the membrane receptor EGFR and the nuclear protein Ki-67Aptamer-dendrimer bioconjugate: a nanotool for therapeutics, diagnosis, and imaging.Receptor-based targeting of therapeutics.Nanodrugs: pharmacokinetics and safety.Therapeutic face of RNAi: in vivo challenges.Polymeric nano-micelles: versatile platform for targeted delivery in cancer.Oral bioavailability: issues and solutions via nanoformulations.The dendrimer paradox--high medical expectations but poor clinical translation.Preclinical studies of dendrimer prodrugs.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).Development, characterization and cancer targeting potential of surface engineered carbon nanotubes.Development and characterization of dexamethasone mesylate anchored on multi walled carbon nanotubes.Nanomedical research in Australia and New Zealand.Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery.A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats.Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy.Poly(γ-glutamic acid)-coated lipoplexes loaded with Doxorubicin for enhancing the antitumor activity against liver tumors.Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration.Dendrimers in combination with natural products and analogues as anti-cancer agents.Traumatic brain injury opens blood-brain barrier to stealth liposomes via an enhanced permeability and retention (EPR)-like effect.Dendritic polymers for dermal drug delivery.PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.
P2860
Q26771189-497C91D3-805E-4DF8-AE75-9336504CE6DAQ26825175-B325C6EC-C16B-4DF7-B394-B0941ED9B823Q28068437-1D5D3B2B-7228-47DB-AAB4-FF80D325FB69Q28087367-2FEE9EAC-5727-4FB6-8FF7-91950916DD95Q30583249-3976F25D-AB9F-4524-8F9F-B86224A85F81Q35851983-C589D185-7A16-418B-8536-598267DEA629Q36010344-77D12D67-E1B9-4DA6-B82D-5BEAE96BDFE9Q36422796-4470B71F-2631-413B-B9B8-E64129820D35Q36953748-84F47665-1950-4F78-A58C-7C7B8D7B6218Q38035033-A8C69EEF-B8AB-4316-BB10-A060AD8F7D2FQ38084739-1FFD5E3C-F5F5-484D-827D-3FCFEDB776BFQ38193067-463A404B-8E91-479D-BCDA-CEC8A285DD65Q38268541-52DB1131-C500-4EB3-B81E-5CE7BE14AF90Q38270690-DFC489AB-E2D4-4DA2-94D3-3E71B683E165Q38349734-E755B236-F8C8-4204-BDA4-955E8A978D7FQ38478308-6879925C-6796-4B07-834A-F362278B6BFAQ38509638-C67925AF-CA4E-45F1-8003-06406A9AECB3Q38676164-C608CCBB-5905-436A-9EE4-EDC478D968AAQ38973975-D4D54248-C6A4-46F3-BD3D-80307C0BB35DQ39131075-37BE3F1E-3F86-426E-B9C2-77D979429449Q39265301-1BB1CAFD-4759-4AEF-AC44-ADA67C89AFF3Q39307127-83F666DE-B934-40F1-8E4C-A6B5B8EFB08BQ39577084-A7A0EB13-7445-4A8A-BA32-06D6EFC4598AQ41117864-C9D3EE57-DBF4-4B57-B92E-118C379BFF6CQ41734074-E0494701-C492-4CD7-AB5F-4903B5B8435EQ42254938-D7F47800-B985-49B4-BDA3-57B48EDA3ECAQ47182893-1D30EE77-D671-4BC0-A1ED-C87D26E255F5Q47333126-2F03C16B-51D4-43DA-9076-9EC2C85715A5Q48126377-4FC2A040-0857-4762-9981-1328939883BBQ50073512-0E1E88E3-3848-42BD-AF75-599E26D23286Q50967733-97A5998E-7723-450B-94E9-E3935FD31EBE
P2860
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A comparison of changes to dox ...... iposome drug delivery systems.
@en
A comparison of changes to dox ...... iposome drug delivery systems.
@nl
type
label
A comparison of changes to dox ...... iposome drug delivery systems.
@en
A comparison of changes to dox ...... iposome drug delivery systems.
@nl
prefLabel
A comparison of changes to dox ...... iposome drug delivery systems.
@en
A comparison of changes to dox ...... iposome drug delivery systems.
@nl
P2093
P50
P1476
A comparison of changes to dox ...... liposome drug delivery systems
@en
P2093
Brian D Kelly
David J Owen
Gian Sberna
Mark Williamson
Victoria M McLeod
P304
P356
10.1016/J.NANO.2011.05.013
P577
2011-06-23T00:00:00Z